Daiken Biomedical Co., Ltd.
Daiken Biomedical Co., Ltd. engages in the research and development of healthy food products. The company is based in Taipei, Taiwan. Daiken Biomedical Co., Ltd. is a subsidiary of Sunfun Info Co., Ltd.
Daiken Biomedical Co., Ltd. (7780) - Net Assets
Latest net assets as of September 2025: NT$5.35 Billion TWD
Based on the latest financial reports, Daiken Biomedical Co., Ltd. (7780) has net assets worth NT$5.35 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$5.65 Billion) and total liabilities (NT$304.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$5.35 Billion |
| % of Total Assets | 94.61% |
| Annual Growth Rate | 139.58% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 209.85 |
Daiken Biomedical Co., Ltd. - Net Assets Trend (2022–2024)
This chart illustrates how Daiken Biomedical Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Daiken Biomedical Co., Ltd. (2022–2024)
The table below shows the annual net assets of Daiken Biomedical Co., Ltd. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.31 Billion | +428.46% |
| 2023-12-31 | NT$247.32 Million | +8.75% |
| 2022-12-31 | NT$227.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Daiken Biomedical Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$55.41 Million | 4.24% |
| Other Components | NT$1.25 Billion | 95.76% |
| Total Equity | NT$1.31 Billion | 100.00% |
Daiken Biomedical Co., Ltd. Competitors by Market Cap
The table below lists competitors of Daiken Biomedical Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Socep Constant
RO:SOCP
|
$134.32 Million |
|
COMER INDS S.P.A.
F:X5Q
|
$134.34 Million |
|
Cahya Mata Sarawak Berhad
PINK:CHYMF
|
$134.39 Million |
|
Zhejiang Extek Technology Co. Ltd. A
SHE:301399
|
$134.40 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
$134.28 Million |
|
Hangzhou Flariant Co Ltd
SHG:605566
|
$134.25 Million |
|
Bintulu Port Holdings Bhd
KLSE:5032
|
$134.22 Million |
|
Prim S.A.
MC:PRM
|
$134.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daiken Biomedical Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 247,322,000 to 1,306,989,000, a change of 1,059,667,000 (428.5%).
- Net income of 106,579,000 contributed positively to equity growth.
- Dividend payments of 3,083,000 reduced retained earnings.
- New share issuances of 1,000,000,000 increased equity.
- Other factors decreased equity by 43,829,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$106.58 Million | +8.15% |
| Dividends Paid | NT$3.08 Million | -0.24% |
| Share Issuances | NT$1.00 Billion | +76.51% |
| Other Changes | NT$-43.83 Million | -3.35% |
| Total Change | NT$- | 428.46% |
Book Value vs Market Value Analysis
This analysis compares Daiken Biomedical Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 50.92x to 0.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | NT$0.38 | NT$19.30 | x |
| 2023-12-31 | NT$0.41 | NT$19.30 | x |
| 2024-12-31 | NT$21.78 | NT$19.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daiken Biomedical Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.15%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.82%
- • Asset Turnover: 0.89x
- • Equity Multiplier: 1.18x
- Recent ROE (8.15%) is below the historical average (37.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 39.65% | 10.19% | 1.67x | 2.33x | NT$67.43 Million |
| 2023 | 64.84% | 13.47% | 1.60x | 3.01x | NT$135.62 Million |
| 2024 | 8.15% | 7.82% | 0.89x | 1.18x | NT$-24.12 Million |
Industry Comparison
This section compares Daiken Biomedical Co., Ltd.'s net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $17,559,023,800
- Average return on equity (ROE) among peers: 8.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daiken Biomedical Co., Ltd. (7780) | NT$5.35 Billion | 39.65% | 0.06x | $134.28 Million |
| Wei Chuan Foods Corp (1201) | $5.55 Billion | 12.34% | 1.69x | $125.16 Million |
| Ve Wong Corp (1203) | $6.25 Billion | 7.16% | 0.53x | $76.18 Million |
| Great Wall Enterprise Co Ltd (1210) | $7.57 Billion | 10.72% | 1.28x | $893.11 Million |
| Charoen Pokphand Enterprise Taiwan Co Ltd (1215) | $5.36 Billion | 14.61% | 0.75x | $839.68 Million |
| Uni-President Enterprises Corp (1216) | $130.79 Billion | 9.49% | 1.59x | $10.01 Billion |
| AGV Products Corp (1217) | $6.27 Billion | 0.76% | 1.01x | $116.99 Million |
| Taisun Enterprise Co Ltd (1218) | $3.67 Billion | 6.42% | 1.09x | $108.34 Million |
| Fwusow Industry Co Ltd (1219) | $3.96 Billion | 5.13% | 1.26x | $99.99 Million |
| Tai Roun Products Co Ltd (1220) | $2.53 Billion | 5.26% | 0.26x | $37.61 Million |
| Formosa Oilseed Processing Co Ltd (1225) | $3.65 Billion | 9.29% | 1.12x | $49.69 Million |